Atomo Diagnostics (ASX:AT1) Shares Buyback Ratio %: -26.75 (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Atomo Diagnostics Shares Buyback Ratio %?

Atomo Diagnostics ASX:AT1 Shares Buyback Ratio % is -26.75 as of Aug. 27, 2026. The stock has 4 warning signs investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Atomo Diagnostics's current shares buyback ratio was -26.75%.

Atomo Diagnostics Shares Buyback Ratio % Related Terms

Atomo Diagnostics Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Atomo Diagnostics's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atomo Diagnostics Shares Buyback Ratio % Chart

Atomo Diagnostics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Shares Buyback Ratio %
Get a 7-Day Free Trial -1.34 -0.40 0.00 -11.97 -15.63

Atomo Diagnostics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.97 0.00 0.00 -15.63 -9.61

Atomo Diagnostics Shares Buyback Ratio % Calculation

Atomo Diagnostics's Shares Buyback Ratio for the fiscal year that ended in Jun. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Jun. 2024 ) - Shares Outstanding (EOP) (A: Jun. 2025 )) / Shares Outstanding (EOP) (A: Jun. 2024 )
=(639.202 - 739.115) / 639.202
=-15.63%

Atomo Diagnostics's Shares Buyback Ratio for the quarter that ended in Dec. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Jun. 2025 ) - Shares Outstanding (EOP) (A: Dec. 2025 )) / Shares Outstanding (EOP) (A: Jun. 2025 )
=(739.115 - 810.175) / 739.115
=-9.61%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of -26.75 mean?
Atomo Diagnostics (ASX:AT1) has a Shares Buyback Ratio % of -26.75 as of Aug. 27, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Atomo Diagnostics and its competitors.
Is Atomo Diagnostics' Shares Buyback Ratio % too high?
Atomo Diagnostics' current Shares Buyback Ratio % is -26.75.
How does Atomo Diagnostics' Shares Buyback Ratio % compare to ABT and SYK?
Atomo Diagnostics' Shares Buyback Ratio % of -26.75 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Medical Devices & Instruments company?
A good Shares Buyback Ratio % depends on the Medical Devices & Instruments industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Atomo Diagnostics and its competitors. Atomo Diagnostics's current Shares Buyback Ratio % is -26.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atomo Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Atomo Diagnostics (ASX:AT1) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.02 — trading 15% below its estimated fair value. The current Shares Buyback Ratio % is -26.75. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Atomo Diagnostics (ASX:AT1), the current Shares Buyback Ratio % is -26.75 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atomo Diagnostics Business Description

Address 3 - 5 George Street, Level 1, Leichhardt, Syndey, NSW, AUS, 2040
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.